Dance Biopharm's Adagio inhaled insulin passes PhI/II; ANI, Sofgen team up for oral soft gel cardiovascular treatment;

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Dance Biopharm welcomed Phase I/II clinical data for its Adagio inhalable insulin candidate for Type 1 diabetes. Release

> ANI Pharmaceuticals ($ANIP) teamed up with Sofgen Pharmaceuticals to develop an oral soft gel to treat cardiovascular diseases. Release

> Researchers at the RIKEN Center for Emergent Matter Science and the University of Tokyo are leading the development of a nanomed that uses energy levels to control the delivery of a therapeutic payload. Article

> TherapeuticsMD began a Phase I study of its estradiol VagiCap to deliver hormone supplements to treat vulvar and vaginal atrophy. Release

> XstalBio launched its CentuRecon delivery tech for highly concentrated biologic drugs prepared in minutes rather than hours. Release

Suggested Articles

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.